2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOPending
Primary objectives:- Determine the value of fluorescence imaging-guided surgery under ambient light conditions for the identification of hybrid tracer-containing SNs as seen on preoperative imaging.Secondary objectives:- Determine the value (…